Bladder Malignanccy

Question 1

which is involved in ca bladder
Aristocholic acid
N acetyl transferase
Glutathiones transferase
All of the above

Answer 1

All

Question 2

Lynch syndrome life time risk of utuc

Answer 2

6%

Question 3

Screen for lynch syndrome in utic if

Answer 3

Based on this association, it has been suggested
that patients with UTUC should be evaluated for
Lynch syndrome if they
(1) are younger than 60 years of age;
(2) have a family history of UTUC, colon cancer
diagnosed before age 60 years, or endometrial
carcinoma; or
(3) have a personal history of colon or
endometrial cancer

Question 4

Decreased risk in women in ubca

Answer 4

Parity late menarche and ocp use

Question 5

Painless gross hematuria at dx

Answer 5

85%

Question 6

Noninvasice gold std

Answer 6

Cytology

Question 7

Mc tcc

Answer 7

Bladder > renal pelvis. Ureter urethra

Question 8

Urachus bladder dome which type

Answer 8

Adenoca than tcc

Question 9

Premalignant lesions

Answer 9

The 2004 World Health Organization classification
system for urothelial neoplasia classifies pre-
malignant lesions as urothelial hyperplasia (flat
and papillary), reactive atypia, urothelial atypia
of unknown significance (AUS), urothelial
dysplasia, and low-grade intraurothelial neoplasic
Metaplasia is benign.

Question 10

Mc stage in bladder

Answer 10

T1

Question 11

Urinary conduit jejunum compli

Ileuma nd colon compli

Answer 11

Jejunum hypochloremic hyperkalemic metab acidosis

Ileum and colon- hyperchloremicb metab acidosis

Question 12

Intravesical therapy rash and granulomatous prostatitis are side effects of

Answer 12

Mitomycin c and bcg respectively

Question 13

Induction and maintenance therapy of bcg for

Answer 13

Induction 6 wks
Maintenance for intermediate - 1 yr
High - 3 yr

Question 14

Bladder sparing feasible when?

Answer 14

tumor presentations associated with successful
bladder-sparing therapy include:
solitary T2 or early T3 tumors(typically <6 cm in
size),
no tumor-associated hydronephrosis,
tumors allowing a visibly complete TURBT,
invasive tumors not associated with extensive
carcinoma in situ, and
urothelial carcinoma histology

Question 15

Immediate inteavesica therapy can be giben in

Answer 15

Low frade low volume Ta disease
Within 24 hrs of turbt
Gemcitabine > mitomycin

Question 16

High risk pathology

Answer 16

Lvi

Micropapillary and prostatic urethra invasion

Question 17

Aggressive histology

Answer 17

Micropapillary
Sarcomatoid
Plasmacytoid

Question 18

T2n0 in bladder

Answer 18

Nact rt fb cystectomy

cisplatin based if adeq egfr

Question 19

Bladder preservation candidates

Answer 19

Less than 6cm t2/3
Max debulking done
Mild hydronephrosis
No extensive tis
Not multifocal

Question 20

Molecular genomictest done for

Answer 20

Stage IIIB

FGFR2 and 3

Question 21

No role for ACT OR NACT IN

Answer 21

Adrno ca or scc bladder

Question 22

Five subtypes of ubca by which study

Answer 22

Lund university

But we folow tgca now- luminal luminal papilalry etc

Question 23

Nmibc clasify by

Answer 23

Uromol

Question 24

FGFR3 highest in

Answer 24

Luminal papillary

Question 25

Mc in females with p53

Answer 25

Basal squamous

Question 26

Mc genomic alteration

Answer 26

TERT 60-80%

Question 27

Mc mutation in Ta

Answer 27

Fgfr3

Question 28

Mc mut in mibc

Answer 28

P53 mc Rb Cdkn2a

Question 29

After nact t2 no adjuvant is

Answer 29

Nact- ddmvac Adjuvant pt34 n+- ddmvac Adjuvant ypt2 n+- nivolumab

Question 30

Stage 4 mets sustemic therapy

Answer 30

``` Cisplatin eligible gemcitabine cispla fb avelumab Ddmvac fb avelu Ineligibke carbogemci fb avelu Atezoli Pembroli ```

Question 31

Radiosensitising chemo for organ preserving crt

Answer 31

Cisplatin fu Cispacli Fu mito